OTCMKTS:IMNPQ

Immune Pharmaceuticals Stock Forecast, Price & News

$0.14
+0.01 (+7.87 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.12
Now: $0.14
$0.15
50-Day Range
$0.01
MA: $0.03
$0.17
52-Week Range
$0.00
Now: $0.14
$0.18
Volume5.47 million shs
Average Volume3.84 million shs
Market Capitalization$2.88 million
P/E RatioN/A
Dividend YieldN/A
Beta0.69
Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On April 2, 2020, the voluntary petition of Immune Pharmaceuticals, Inc. along with its affiliates, for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on February 17, 2020.
Immune Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:IMNPQ
CUSIPN/A
CIKN/A
Phone201-464-2677
Employees7
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$2.88 million
Next Earnings DateN/A
OptionableNot Optionable

Headlines

News for Immune Pharmaceuticals Inc Registered Shs
December 30, 2020 |  markets.businessinsider.com
See More Headlines

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1952nd out of 2,021 stocks

Pharmaceutical Preparations Industry

758th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.14
+0.01 (+7.87 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMNPQ News and Ratings via Email

Sign-up to receive the latest news and ratings for IMNPQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Immune Pharmaceuticals (OTCMKTS:IMNPQ) Frequently Asked Questions

What stocks does MarketBeat like better than Immune Pharmaceuticals?

Wall Street analysts have given Immune Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Immune Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Immune Pharmaceuticals?

Immune Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 25,100 shares, an increase of 1,221.1% from the March 15th total of 1,900 shares. Based on an average trading volume of 16,563,700 shares, the short-interest ratio is currently 0.0 days.
View Immune Pharmaceuticals' Short Interest
.

Who are Immune Pharmaceuticals' key executives?

Immune Pharmaceuticals' management team includes the following people:
  • Mr. John P. Clark, Controller & Principal Accounting Officer (Age 50, Pay $175k)
  • Mr. Gary H. Rabin, Interim CEO & Director (Age 56)
  • Mr. Christine J. Petraglia, Director of Investor Relations
  • Ms. Anna Baran-Djokovic, Director of Corp. Affairs
  • Dr. Miri Ben-Ami, Pres of Immune Oncology Pharmaceuticals Inc
  • Dr. Boris Shor, Exec. Director of R&D & Scientific Partnerships
  • Mr. Ranch C. Kimball, Strategic Advisor

Who are some of Immune Pharmaceuticals' key competitors?

What is Immune Pharmaceuticals' stock symbol?

Immune Pharmaceuticals trades on the OTCMKTS under the ticker symbol "IMNPQ."

How do I buy shares of Immune Pharmaceuticals?

Shares of IMNPQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immune Pharmaceuticals' stock price today?

One share of IMNPQ stock can currently be purchased for approximately $0.14.

How much money does Immune Pharmaceuticals make?

Immune Pharmaceuticals has a market capitalization of $2.88 million.

How many employees does Immune Pharmaceuticals have?

Immune Pharmaceuticals employs 7 workers across the globe.

What is Immune Pharmaceuticals' official website?

The official website for Immune Pharmaceuticals is www.immunepharma.com.

Where are Immune Pharmaceuticals' headquarters?

Immune Pharmaceuticals is headquartered at 1 BRIDGE PLAZA N SUITE 270, FORT LEE NJ, 07024.

How can I contact Immune Pharmaceuticals?

Immune Pharmaceuticals' mailing address is 1 BRIDGE PLAZA N SUITE 270, FORT LEE NJ, 07024. The company can be reached via phone at 201-464-2677 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.